UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016158
Receipt number R000018750
Scientific Title Comparison of alendronate and teriparatide for the bone mineral density around implant after total hip arthroplasty
Date of disclosure of the study information 2015/01/09
Last modified on 2015/01/08 11:34:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of alendronate and teriparatide for the bone mineral density around implant after total hip arthroplasty

Acronym

RCT for BMD loss after THA
teriparatide vs alendronate

Scientific Title

Comparison of alendronate and teriparatide for the bone mineral density around implant after total hip arthroplasty

Scientific Title:Acronym

RCT for BMD loss after THA
teriparatide vs alendronate

Region

Japan


Condition

Condition

cases after primary total hip arthroplasty

Classification by specialty

Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effect of teriparatide for the prevention of BMD loss after THA comparing with alendronate in a randomized controlled trial

Basic objectives2

Others

Basic objectives -Others

Comparison of bone metabolism markers

Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Change of bone mineral density in teriparatide treatment, alendronate treatment, and control group

Key secondary outcomes

Change of bone formation markers in teriparatide treatment, alendronate treatment, and control group


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

teriparatide daily administration (Forteo 20 ug, Eli Lilly Japan K.K.) beginning on postoperative week 2 and continuing until week 48

Interventions/Control_2

weekly administration of alendronate (Bonalon 35 mg, Teijin Pharma Limited)
beginning on postoperative week 2 and continuing until week 48

Interventions/Control_3

no medication

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Primary total hip arthroplasty cases
applicable for standardized implant
under informed consent

Key exclusion criteria

cases of malignant tumor
cases with difficulty of one year follow-up

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Naomi Kobayashi

Organization

Yokohama City University

Division name

Orthopaedic surgery

Zip code


Address

3-9 Fukuuram Kanazawa-ku, Yokohama, Japan

TEL

045-787-2655

Email

naomik58@aol.com


Public contact

Name of contact person

1st name
Middle name
Last name Naomi Kobayashi

Organization

Yokohama City University

Division name

Orthopaedic surgery

Zip code


Address

3-9 Fukuuram Kanazawa-ku, Yokohama, Japan

TEL

045-787-2655

Homepage URL


Email

naomik58@aol.com


Sponsor or person

Institute

Yokohama City University

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

横浜市立大学医学部付属病院


Other administrative information

Date of disclosure of the study information

2015 Year 01 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 07 Month 01 Day

Date of IRB


Anticipated trial start date

2011 Year 12 Month 01 Day

Last follow-up date

2014 Year 09 Month 30 Day

Date of closure to data entry

2015 Year 01 Month 10 Day

Date trial data considered complete

2015 Year 01 Month 10 Day

Date analysis concluded

2015 Year 01 Month 10 Day


Other

Other related information



Management information

Registered date

2015 Year 01 Month 08 Day

Last modified on

2015 Year 01 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018750


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name